Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

13.07USD
23 Apr 2018
Change (% chg)

$-0.31 (-2.35%)
Prev Close
$13.39
Open
$13.30
Day's High
$13.38
Day's Low
$12.68
Volume
328,827
Avg. Vol
312,126
52-wk High
$27.48
52-wk Low
$9.83

Select another date:

Wed, Mar 21 2018

BRIEF-Achaogen Says FDA to Review Plazomicin By June 25

* ACHAOGEN ANNOUNCES DATE OF FDA ADVISORY COMMITTEE MEETING FOR PLAZOMICIN

BRIEF-Robert Duggan Reports 14.2 Pct Stake In Achaogen Inc As Of March 12 Compared To A Stake Of 13.2 Pct As Of Dec 6

* ROBERT DUGGAN REPORTS 14.2 PERCENT STAKE IN ACHAOGEN INC AS OF MARCH 12 COMPARED TO A STAKE OF 13.2 PERCENT AS OF DECEMBER 6 -SEC FILING Source text: (http://bit.ly/2DoINbl) Further company coverage:

BRIEF-Achaogen Enters Into New $50 Million Secured Credit Facility With Silicon Valley Bank

* ACHAOGEN ENTERS INTO NEW $50 MILLION SECURED CREDIT FACILITY WITH SILICON VALLEY BANK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Achaogen Reports Q4 Loss Per Share $0.98

* ACHAOGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Achaogen Announces Upgraded Status For Plazomicin Fill Manufacturer

* SAYS ‍FDA CLASSIFIED OUTCOME OF ITS Q4 2017 REINSPECTION OF PFIZER'S MCPHERSON FACILITY AS VOLUNTARY ACTION INDICATED​ Source text for Eikon: Further company coverage:

BRIEF-Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-Scape

* ACHAOGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST CLINICAL TRIAL OF ORALLY-ADMINISTERED ANTIBACTERIAL CANDIDATE C-SCAPE

BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin

* ACHAOGEN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR PLAZOMICIN FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND BLOODSTREAM INFECTIONS

BRIEF-Achaogen Appoints Blake Wise Chief Executive Officer

* ACHAOGEN INC - KENNETH HILLAN TO BECOME PRESIDENT, RESEARCH AND DEVELOPMENT

BRIEF-Achaogen reports Q3 loss per share $0.85

* Achaogen reports third quarter 2017 financial results and provides corporate update

BRIEF-Achaogen submits Plazomicin new drug application to FDA

* Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections

Select another date: